Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis.

Autor:	Rodríguez-Vargas GS; Research Institute, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.; Rheumatology, Biomab - Center for Rheumatoid Arthritis, Bogotá, Colombia., Santos-Moreno P; Rheumatology, Biomab - Center for Rheumatoid Arthritis, Bogotá, Colombia., Rubio-Rubio JA; Research Institute, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia., Bautista-Niño PK; Research Laboratory, Fundación Cardiovascular de Colombia (FCV), Bucaramanga, Colombia., Echeverri D; Cardiovascular Prevention Program, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia., Gutiérrez-Castañeda LD; Research Institute, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.; Basic Sciences Laboratory, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia., Sierra-Matamoros F; Epidemiology, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia., Navarrete S; Basic Sciences Laboratory, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia., Aparicio A; Basic Sciences Laboratory, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia., Saenz L; Cardiovascular Prevention Program, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia., Rojas-Villarraga A; Research Institute, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2022 Jul 05; Vol. 9, pp. 894577. Date of Electronic Publication: 2022 Jul 05 (Print Publication: 2022).
DOI:	10.3389/fcvm.2022.894577
Abstrakt:	Introduction: The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is 1.5-2 times higher than the general population. The fundamental risk factor for CVD is age, related to alterations at the arterial level. The aim of the study was to compare vascular age (VA) in RA patients under a strict treat-to-target (T2T) strategy with Osteoarthritis (OA) patients without strict follow up and to assess the influence of inflammaging (chronic, sterile, low-grade inflammation related to aging) and metabolic markers on VA. Materials and Methods: This was an analytical cross-sectional study. Patients with RA (under a strict a T2T strategy) and OA patients without strict clinical follow-up were included. Patients with a history of uncontrolled hypertension, CVD, and/or current smoking were excluded. Sociodemographic, physical activity, and toxic exposure data were obtained. Waist-hip ratio and body mass index (BMI) were measured. DAS-28 (RA) and inflammatory markers, lipid profile, and glycaemia were analyzed. Pulse wave velocity (PWV) was measured (oscillometric method, Arteriograph-TensioMed®). VA was calculated based on PWV. Eleven components of inflammaging [six interleukins, three metalloproteinases (MMP), and two tissue inhibitors of metalloproteinases (TIMP)] were evaluated (Luminex® system). Univariate and bivariate analyzes (Mann Whitney U and chi-square) and correlations (Spearmans Rho) were done to compare the two groups. Results: A total of 106 patients (74% women) were included, 52/RA and 54/OA. The mean age was 57 (Interquartile range - IQR 9 years). The BMI, waist circumference, and weight were higher in patients with OA ( p < 0.001). RA patients had low disease activity (DAS-28-CRP). There were no differences in VA, inflammaging nor in PWV between the two groups. VA had a positive, but weak correlation, with age and LDL. In group of RA, VA was higher in those who did not receive methotrexate ( p = 0.013). LDL levels correlated with MMP1, TIMP1, and TIMP2. Conclusions: When comparing RA patients with low levels of disease activity with OA patients with poor metabolic control, there are no differences in VA. Furthermore, methotrexate also influences VA in RA patients. This shows that implemented therapies may have an impact on not only the inflammatory state of the joint but also CVD risk. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Rodríguez-Vargas, Santos-Moreno, Rubio-Rubio, Bautista-Niño, Echeverri, Gutiérrez-Castañeda, Sierra-Matamoros, Navarrete, Aparicio, Saenz and Rojas-Villarraga.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu